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Podocytes synthesize the majority of the glomerular basement
membrane components with some contribution from the
glomerular capillary endothelial cells. The anionic charge of
heparan sulfate proteoglycans is conferred by covalently
attached heparan sulfate glycosaminoglycans and these are
thought to provide critical charge selectivity to the glomerular
basement membrane for ultrafiltration. One key component in
herparan sulfate glycosaminoglycan assembly is the Ext1 gene
product encoding a subunit of heparan sulfate co-polymerase.
Here we knocked out Ext1 gene expression in podocytes
halting polymerization of heparin sulfate glycosaminoglycans
on the proteoglycan core proteins secreted by podocytes.
Glomerular development occurred normally in these knockout
animals but changes in podocyte morphology, such as foot
process effacement, were seen as early as 1 month after birth.
Immunohistochemical analysis showed a significant decrease
in heparan sulfate glycosaminoglycans confirmed by
ultrastructural studies using polyethyleneimine staining.
Despite podocyte abnormalities and loss of heparan sulfate
glycosaminoglycans, severe albuminuria did not develop
in the knockout mice. We show that the presence of
podocyte-secreted heparan sulfate glycosaminoglycans is not
absolutely necessary to limit albuminuria suggesting the
existence of other mechanisms that limit albuminuria.
Heparan sulfate glycosaminoglycans appear to have functions
that control podocyte behavior rather than be primarily an
ultrafiltration barrier.
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Proteoglycans (PGs) can be considered to be hypervariable
molecules with respect to structure and function; the
hypervariability being conferred by information contained
in the nature of the core protein and in the covalently
attached glycosaminoglycan (GAG) chains.1 Changes in
the pericellular microenvironment affect not only the levels
of synthesis of PG core proteins but also the organization
of critical elements within the GAG chains, such as
carbohydrate composition, sulfation, and epimerization.2
Research on PGs over the past 25 years has allowed the
scientific community to move beyond the past concep-
tual constraints that relegated PGs to simple structural
elements in the extracellular matrix. Most researchers now
embrace the fact that PGs serve many critical functions
in tissues, such as control of cell differentiation, migration,
and adhesion.3
In the field of renal biology, the classic experiments of
Kanwar et al.4 provided the foundation from which a
paradigm evolved that supported the concept that heparan
sulfate (HS)-GAG chains on HSPGs served as a filtration
medium in the glomerular capillary wall. Using short-term
heparanase III treatment to eliminate HS-GAG chains from
the glomerular capillary basement membrane (GBM), they
were able to alter the permselectivity of the GBM to native
ferritin. The results led Kanwar et al. to postulate that the
highly negative charged HS-GAGs served to impart charge
selectivity to the filtration barrier in the kidney. Since that
first report, numerous other studies using similar and
alternative approaches had, in part, validated this observa-
tion. Subsequent studies made an association between the
loss of HS-GAGs from the glomerular capillary wall and the
development of albuminuria in the progression of nephro-
pathy in individuals afflicted with long-term, poorly
controlled diabetes.
The assembly of HS-GAG on PG core proteins is a proces-
sive biosynthetic event involving at least five separate glyco-
syltransferases, sulfotransferases, and epimerases (Figure 1).
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Initially a common linkage region of glucuronic acid–galac-
tose–galactose–xylose (GlcAb-1,3 Galb-1,3 Galb-1,4
Xylb) is assembled on a core protein serine residue. Once
this four carbohydrate linkage region is assembled, an
additional GlcNAc is added by the EXTL3 enzyme.5
Subsequent heparan chain elongation/polymerization occurs
by the actions of the HS-copolymerase EXT1/EXT2.6 Of the
two enzymes present in the copolymerase, the absence of
EXT1 from the copolymerase results in complete loss of the
HS polymerase activity.
The major biosynthetic source of basement membrane
(BM) material in the glomerular capillary wall has been
thought to be the visceral epithelial cell, or podocyte, which
resides on the external surface of the glomerular capillary
wall.7,8 Using a Cre-lox approach, we mutated the Ext1 gene
in glomerular podocytes by selectively breeding mice in which
loxP sites flanked exon 1 of the Ext1 allele (Ext1floxed/floxed)9
with mice transgenic for Cre recombinase, the expression of
which was driven by a podocin (NPHS2) promoter (2.5P-Cre
mice10). Since podocin is only expressed in podocytes within
the renal glomerulus, the 2.5P-Cre promoter construct leads to
podocyte-specific expression of Cre recombinase. For the sake
of brevity, the resultant mutant mice (2.5P-Cre, Ext1floxed/floxed)
have been called PEXTKO mice (podocyte-specific Ext1
knockout; Figure 2).
RESULTS
The fact that activation of the podocin gene does not occur in
podocytes until the capillary loop phase of nephrogenesis10
led us to predict that the basic process of nephrogenesis
should be unaffected in PEXTKO animals, the consequences
of the targeted knockout occurring downstream during
subsequent glomerular growth and maturation. Predictably,
if the sole function of HS-GAGs attached to PG core proteins
within the GBM was to determine size/charge selectivity for
glomerular ultrafiltration, the effects of eliminating HS-GAG
should have resulted in postnatal lethality (3–4 weeks) from
severe proteinuria in a manner similar to that had been
shown in a laminin b2 knockout animal model.11 Surpris-
ingly, no perinatal morbidity and lethality were seen in any of
the PEXTKO animals. Body weights and combined kidney
weights did not show a statistically significant difference in
young (2 months) or older (8 months) PEXTKO animals
when compared to control. Renal hypertrophy, as indicated
by the kidney weight/body weight ratio was not seen in
young animals (2 months), but was significant in PEXTKO
animals at 8 months of age when compared to controls
(Figure S1).
Our initial routine light microscopy examination
of kidneys taken from 1- and 3-month-old control and
PEXTKO animals did not show any differences (Figure 3a–d).
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Figure 1 | The cartoon depicts a simplified scheme of the assembly and extension of HS-GAG chains on a PG core protein. The initial
step in the assembly of the HS-GAG chain (and common to all HS and chondroitin sulfate-bearing PGs) is the assembly of a linker
tetrasaccharide (glucuronosyl-b 1,3-galactosyl-b 1,3-galactosyl-b 1,4 xylose) attached to a serine residue present in the proteoglycan core
protein. Each carbohydrate residue in the linkage region is assembled by a specific glycosyltransferase. In the case of HS-GAG, following the
assembly of the linkage region, an N-acetyl glucosamine residue (a-GlcNAC) is the next carbohydrate residue attached to the linkage region
by the enzyme EXTL3. Once assembled, the pentasaccharide is recognized by heparan sulfate copolymerase, EXT1/EXT2. The HS
copolymerase extends the nascent GAG chain by the sequential addition of a glucuronic acid (UA) and N-acetyl glucosamine (GLN), which
are derived from UDP precursors, forming a repetitive copolymer of these subunits (GlcNAca1–4GlcAb1–4)n. For the sake of simplification,
the subsequent events in the process, such as deacetylation, sulfation, and uronic acid epimerization, which occur during HS chain
elongation are not depicted.
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As the animals aged, the proximal tubule epithelial cells
developed an abnormal vacuolated cytoplasm (Figure 3f
and h). Staining of tissue sections with Oil Red O and with
osmium tetroxide (data not shown) was negative, indicating
that the vacuoles were not filled with lipid. The presence of
vacuoles in proximal tubule epithelial cells was not seen in
age-matched controls (Figure 3e, g).
Immunohistochemistry using a monoclonal antibody
directed against an epitope present on HS-GAGs (antibody
HS4C3; Figure 4a–f)12 showed a significant, persistent decrease
in staining for HS-GAG in the glomerular capillary wall.
Glomerular staining for HS-GAG was not entirely abolished
within the renal glomerulus, since mesangial cells and capillary
endothelial cells would still possess the ability to assemble HS-
GAGs. Immunohistochemistry using monoclonal antibodies
directed against chondroitin-6 (C-6)-sulfated epitopes (Figure
4g and h) investigated the possibility that one potential default
pathway to maintain anionic charge density might be the
de novo initiation of synthesis/substitution of C-6-sulfated
GAGS on PG core proteins. However, there was no apparent
difference in the pattern of distribution of C-6-sulfated GAGs
between control and PEXTKO animals. By early adulthood
(3 months of age; Figure 4i), the glomeruli of PEXTKO
animals showed that persistent, significant hypertrophy existed
when compared to control animals.
To investigate potential changes in the protein composi-
tion of the GBM, tissue sections from 1-, 3-, and 8-month-
old animals were immunostained with antibodies against the
g1 chain of laminin (not shown), agrin, and perlecan PG core
proteins (Figure 5a–l). Despite the hypertrophy seen in
PEXTKO glomeruli, there was no readily apparent difference
in the intensity nor patterns of immunostaining for g1
laminin (not shown) or perlecan core protein (Figure 5a, b, e,
f, i and j). In contrast, glomeruli in the PEXTKO animals had
comparatively higher intensities of immunostaining for agrin
core protein at every time interval examined (Figure 5c, d, g,
h, k and l).
Electron microscopy studies of the glomeruli from
PEXTKO animals showed significant ultrastructural changes
at 1 month of age (Figure 6b), some of which persisted into
adulthood (Figure 7) when compared to age-matched control
animals (Figure 6a). In tissue sections from 1-month-old
animals, the basic organization of the glomerular podocytes
was abnormal, with obvious foot process effacement (Figure
6b) occurring along the perimeter of the GBM. Microvilli
were found on the apical surface of the podocytes from
1-month-old animals (Figure 6b). In portions of the
glomerular capillary walls in the kidneys of some animals,
there were areas where the normal developmental process of
glomerular basement ‘fusion’ may have failed to occur, as
indicated by the presence of a double BM in the capillary wall
(Figure 6b, inset). In addition, the presence of numerous
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Figure 2 | The results of a PCR-based genotype screen for the
presence of Ext1fl/fl alleles and the 2.5P-Cre transgene.
Amplification of the wild-type Ext1 allele (Ext1wt) yields a product
of 360 bp, whereas the Ext1floxed allele yields a larger 460-bp
product. The 2.5P-Cre product is 268 bp. The boxed-in area of the
gel represents an animal with the PEXTKO genotype.
1 
m
on
th
3 
m
on
th
s
8 
m
on
th
s
12
 m
on
th
s
250 µm
a b
c d
e f
g h
Figure 3 | The micrographs of tissue sections from control
(a, c, e, g) or PEXTKO animals (b, d, f, h) stained with
hematoxylin and eosin. The age-matched animals were 1 (a, b),
3 (c, d), 8 (e, f), and 12 (g, h) months of age. Overall there were no
profound differences in either glomerular or tubular structure
between control and PEXTKO kidney at 1 and 3 months of age; no
differences among the control animals were seen at any age
examined. At 8 months of age, there were very apparent changes
in the proximal tubule epithelial cells in the PEXTKO animals
(f, arrows), the cells of which had large vacuoles present in the
cytoplasm. These changes persisted in older PEXTKO animals (h).
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‘outpockets’ or ‘humps’ of BM material on outside of the
glomerular capillary wall was also seen. Although not
common in the normal adult glomerulus, during glomerular
maturation this particular morphology is indicative of
regions of the GBM where newly synthesized material is
being spliced into existing GBM.13 In older animals (43
months of age), both ‘outpockets’ of BM material, foot
process effacement, and the presence of microvilli persisted
(Figure 7) but no evidence of a ‘double’ or ‘split’ BM was
seen, suggesting that this particular abnormality may not
persist in older animals. Despite changes that would be
considered an indicator of glomerular dysfunction, only a
minor albuminuria that was not statistically significant
relative to controls developed in young (2 months of age)
PEXTKO animals (Figure 8). Over time (8 months of age),
the albuminuria gradually increased but still was mild and
not statistically significant from control animals (Figure 8).
To corroborate the immunohistochemistry data, which
showed the loss of HS-GAG from the GBM (Figure 4),
polyethylenimine (PEI) staining was done to demonstrate the
presence/absence of anionic sites in the GBM (Figure 9a
and b). In control animals (Figure 9a and c), PEI labeled the
GBM in a consistent ratio of 2:1 lamina rara externa
(LRE):lamina rara interna (LRI) sites (Figure 9c). In
PEXTKO mice at each age examined, (Figure 9b and c), the
number of anionic sites per unit length GBM decreased
significantly as did the labeling ratio (1:3 LRE:LRI sites).
Thus, the development of a very mild albuminuria in the
PEXTKO mouse was gradual, first seen in the 2-month-old
animals by ELISA-based assays (Figure 8d) and was
associated with foot process effacement and loss of anionic
sites in the LRE. Over time, the albuminuria gradually
increased but still remained relatively mild, its gradual
increase associated with abnormal tubular epithelial
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Figure 4 | The micrographs are of tissue sections of kidney immunostained with antibodies against HS-GAGs (antibody HS4C3, a–f)
or chondroitin sulfate GAGs (CS-GAGs, antibody 3B3, g, h). (a–f) Deconvolved images resolving a single focal plane, (b, d, f) glomeruli
from PEXTKO animals of 1, 3, and 8 months of age respectively. (a, c, e) Age-matched control animals. (g, h) Glomeruli from 3-month-old
control and PEXTKO animals, respectively. In control glomeruli (a, c, e), the HS4C3 antibody immunostains the pericapillary (arrows)
and perimesangial GBM as well as the mesangial matrix (M). In PEXTKO glomeruli (b, d, f), HS4C3 stains primarily the mesangial matrix (M),
with significantly reduced staining in the pericapillary GBM. The glomeruli in (g) (control) and (h) (PEXTKO) show similar patterns of
mesangial staining (M) with no GBM staining, indicating that CS-GAGs were not substituted on GBM proteoglycan core proteins as a
default mechanism. (i) The results of morphometric measures of glomerular area in control and PEXTKO animals. At both ages examined,
the glomeruli from PEXTKO animals were hypertrophic compared to age-matched control animals (*Po0.0001); and glomerular
hypertrophy gradually increased over time (**Po0.006).
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morphology (Figure 3f and h), and the persistent loss of
anionic sites in the GBM (Figure 9c).
DISCUSSION
At first glance, the renal morphological and functional
phenotypes seen in the PEXTKO mouse appears to defy several
widely accepted paradigms in the field of renal biology. The
data show that despite the selective loss of HS-GAG from the
GBM, in particular the LRE, the PEXTKO mice do not appear
to develop albuminuria until 2 months of age, the albuminuria
being relatively minor. In older animals (8 months), the
albuminuria was slightly increased compared to controls but
still was relatively minor. To date (424 months), outside of the
experimental protocols, none of the PEXTKO mouse strain
animals have suffered any morbidity or mortality.
Several investigations of the glomerular ultrafiltration
surface used degradation with specific carbohydrate lyases4,14
or neutralization of anionic charge15,16 as methods to probe
the function of the carbohydrate elements within the GBM.
In contrast to the in situ approach of Kanwar et al.4 which
showed that the anionic charge on GBM HS-GAGs conferred
charge selectivity to the barrier, a recent study by Wijnhoven
et al.,14 which used an in vivo approach to remove HS from
the GBM, showed that injection of rats with heparanase III
did not result in the development of acute proteinuria.
Interestingly, in vivo digestion of neuraminic acid residues
did result in acute proteinuria.
Although these approaches have yielded very significant
information about the behavior/function of carbohydrate
elements of the GBM, the technical limitations of those
studies placed constraints on the temporal interval over
which alterations in the dynamic of the nephron and its GBM
could be observed. Molecular genetic approaches now permit
longer term observation of either global or discrete tissue-
specific perturbations of the glycobiology of BMs. One global
approach, which eliminated the primary HS-GAG acceptor
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Figure 5 | The micrographs are of tissue sections immunostained with antibodies against either perlecan (antibody A7L6; a, b, e,
f, i, j) and agrin (antibody K-17; c, d, g, h, k, l). Glomeruli from control (a, c, e, g, i, k) and PEXTKO animals (b, d, f, h, j, l) are presented
in an age-matched manner identical to Figure 1. To show staining intensity differences in the agrin-stained glomeruli, the exposure
for each image pair was set to the specimen with the brightest intensity, and both control and PEXTKO images were subsequently
imaged at the same exposure setting. For both proteoglycan core protein species, there is no visible change in the pattern of distribution
within the glomerulus. The distribution of perlecan staining in both control and PEXTKO animals is identical, being strongest in the
mesangial matrix and weaker staining seen in the glomerular capillary wall. In contrast, at each age (1, 3, and 8 months) the intensity
for agrin staining in the glomeruli from PEXTKO animals is greater than that seen in the control animals.
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site (the HSPG2D3/D3 mouse) within the coding region for the
BM PG perlecan,17 showed minimal effect on glomerular
ultrafiltration and podocyte morphology unless a supraphy-
siologic stressor was placed upon the system.18 The presence
of glycosylated agrin, which is currently considered to be the
major GBM HSPG, would have served to maintain normal
physiologic ultrafiltration function in this model. However,
the recent study reporting the production of a podocyte-
specific agrin knockout mouse model, which led to the
depletion of BM HS-GAGs associated with the agrin core
protein, also showed little effect on overall glomerular
morphology and renal function.19 Another approach used
global expression of heparanase in a transgenic model20 to
enhance HS-GAG degradation. Analysis of the phenotype of
the model showed intact HSPGs were still assembled and
exported by cells, albeit processed by the active heparanase
enzyme into a lower molecular weight species of PG. The net
outcome in this transgenic model was only mild albuminuria.
The morphologic features seen in the PEXTKO mouse can
be associated with several glomerular diseases, but appear to
align with those described for minimal change glomerulo-
pathy (MCG) in humans.21 MCG (also known as Minimal
Change Nephrotic Syndrome) accounts for approximately
90% of nephrotic syndrome seen in juvenile patients under
the age of 10 years and 50% of nephrotic syndrome in
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Figure 6 | The electron micrographs show glomeruli from adult control animals (a, 2.5P-Creþ /Ext1wt/wt) and PEXTKO (b, 2.5P-
Creþ /Ext1fl/fl) animals. In control animals, the basic architecture of the glomeruli from these animals is normal, with no visible sign of foot
process effacement or obvious BM ‘outpockets.’ The inset in the corner of each larger micrograph is a higher magnification of the area
in the main micrograph outlined by the dashed line. (b) An electron micrograph of a glomerular capillary wall from a 1-month-old
PEXTKO mouse. Within the picture are the cell bodies of two podocytes (P) having abnormal, effaced foot processes (arrows). On the apical
surface of the podocytes, microvilli (area denoted by M) can be found. The GBM also shows irregularities, having numerous outpockets
or ‘humps’ (arrowheads) on the podocyte side of the GBM. The inset shows an enlargement of the boxed-in area of the capillary wall.
In this region, the BM has an abnormal appearance, resembling two separate BMs. The presence of the outpockets, along with the double
BM, suggests the possibility that GBM fusion, a normal developmental process, has been delayed in this area of the glomerulus. The
presence of a double BM has not been seen in older (43 months) animals.
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Figure 7 | The electron micrographs map the changes in
glomerular capillaries seen in adult (3 months) PEXTKO
animals. (a) Low magnification electron micrograph of several
glomerular capillaries. The arrowheads in the picture denote areas
where there are BM ‘outpockets’ in the capillary wall. Although in
developing/maturing kidneys this type of morphology is
associated with areas where active BM synthesis/splicing is
occurring, it is also possible that these areas could be areas of
basement membrane remodeling by podocytes. The arrows point
to two abnormally attenuated primary processes of a podocyte.
The boxed-in area of (a) is shown in higher magnification in (b).
The apical surface of the podocyte shows the abnormal presence
of microvilli (M) and the region of foot process in the basal side of
the podocyte is severely effaced. Despite the presence of the
‘outpockets’ of BM material, in the normal thickness GBM the
classic LRE-lamina densa (LD)-LRI organization is easily seen,
suggesting that BM assembly may be essentially normal.
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juveniles beyond that age.21 The etiology of MCG in humans
is not entirely clear and to some extent multifactorial
(idiopathic or secondary) in nature.21 Although we are not
proposing the PEXTKO mouse as a model for MCG since the
mutant mouse does not mimic the etiology of MCG, it does
exhibit several morphological changes that have been
associated with MCG. Unlike MCG, however, severe
proteinuria does not develop in PEXTKO mice. One key
morphologic change seen in the PEXTKO mouse in common
with MCG is the lack of obvious glomerular lesions in light
microscopy but the presence of tubular epithelial cell
changes. The observed glomerular ultrastructural changes
are consistent with that reported for MCG and include
podocyte foot process effacement, microvillous transforma-
tion but with relatively normal BM thickness.21 The
basic lesion of the PEXTKO model, that is, the loss of the
ability of the podocytes to synthesize and deliver intact
HSPGs to the GBM also corresponds to some extent by
previous studies in humans, which showed that in MCG
there is a loss of GBM HS-GAGs without the loss of the
agrin core protein.22
In the case of the PEXTKO mouse, albuminuria detectable
by SDS-polyacrylamide gel electrophoresis (PAGE) is coin-
cident with loss of HS-GAG only after visible changes in the
proximal tubules of the kidney are seen. However, ELISA-
based assays showed that the PEXTKO mouse develops a
slight but not statistically significant increase in urinary
albumin excretion (Figure 8d) at 2 months of age that was
not initially evident by SDS-PAGE. The same method of
urinalysis of 8-month-old animals shows that the albumi-
nuria is increased in PEXTKO mice compared to control
animals (Figure 8d), an observation consistent with the SDS-
PAGE data. However, the albuminuria seen at both 2 and 8
months was mild and did not reach statistical significance. In
light of the discussion within one of the above paragraphs,
which indicated that the loss of HS-GAG from the GBM may
only have modest effects on overall ultrafiltration, led us to
consider that the protein retrieval capacity of the proximal
tubules in murine nephron might be greater than previously
thought and proximal tubule elements could be capable of
developing a compensatory response to handle a moderate
degree of protein overload in younger PEXTKO animals. This
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Figure 8 | (a) Silver-stained gel of urinary proteins from representative age-matched (3 months) control and PEXTKO animals
(collection interval 24 h). At 3 months of age, there was no discernable difference in albumin between control and PEXTKO animals.
At 8 months of age, a slight amount of albuminuria is present in the PEXTKO animals compared to control. In ELISA-based assays for
urinary albumin, a slight increase in urinary albumin (b) was seen in PEXTKO animals at 2 and 8 months of age when compared to controls,
albeit the differences did not reach statistical significance (n¼ 5 animals per group). Urinary creatinine levels (c), as measured by a
commercially available plate assay, were comparable between both groups at both ages. The ratio of urinary albumin/creatinine (d) was
increased in PEXTKO animals at both ages but the differences did not reach statistical significance.
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premise was recently buttressed in a study by Russo et al.23
which used intravital multiphoton microscopy to show that
albumin delivery to the normal rodent proximal tubule was
greater than previously indicated by micropuncture studies.
Their reported glomerular sieving coefficient of 0.034
suggests that levels of albumin that would be considered in
the nephrotic range are actually routinely delivered to the
proximal tubules on a daily basis. Thus, the proximal tubule
epithelial cells are capable of retrieving a greater than
anticipated protein load in normal animals, resulting in no
measurable albuminuria. Further experiments in their report,
which used a puromycin aminonucleoside nephrosis-induced
nephritis rat model, showed that the development of
proteinuria was coincident with a dysfunction in proximal
tubule epithelial retrieval activity. Thus, it is possible in the
PEXTKO model that some type of albumin retrieval
mechanism becomes upregulated and compensates for an
increased protein delivery to the tubule system. And, if this is
the case, then over time decompensation/defeat of this
mechanism gradually occurs leading to the measurable
albuminuria seen in our model.
The presence of podocyte foot process effacement despite
no loss of HSPG core protein in PEXTKO mouse model
strongly suggests that the HS-GAGs on HSPGs secreted by
podocytes in some way have direct effects on the foot process
organization of the glomerular podocytes. The fact that
minor albuminuria develops several months prior to the
observed tubule damage suggests that foot process effacement
may be a contributing factor in our observations. The
mechanism by which the HS-GAG loss affects podocyte foot
process organization in the PEXTKO model is currently
under investigation. Although one might speculate that a
single molecular PG species could be the nidus of such
changes, because of the diverse functions of PGs/GAGs the
eventual answer could involve several different lines of
reciprocal cell–matrix interactions. However, the fact that
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Figure 9 | The micrographs in (a, b) are of two adjacent glomerular capillary walls from control (a) and PEXTKO (b) animals
(8 months of age shown) that were labeled with PEI, a probe for the presence of anionic sites in the GBM. In control animals, PEI label
can be found immediately subtending the podocyte foot processes and endothelial cells (black arrows) in the lamina rara externa (LRE) and
lamina rara interna (LRI), respectively. The labeling ratio for PEI in these areas is approximately 2:1 (LRE:LRI). The amount of PEI labeling in
the PEXTKO animal is significantly decreased (black arrows). The graph in (c) compares the number of PEI sites in the LRE and LRI from
control and PEXTKO kidneys of 2 and 8 months of age. The data show a significant decrease in the amount of PEI label in the LRE
(*Po0.0001) in both age groups. An age-related decrease in anionic sites in the LRE was also seen in control animals (@P¼ 0.0004). In the LRI
of PEXTO animals, a decrease in anionic sites was also seen at both 2 months (**P¼ 0.0004) and 8 months (#Po0.0019) compared to
controls. control 2 months, PEXTKO 2 months, control 8 months, PEXTKO 8 months.
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the GBM-specific agrin knockout mouse does not develop
foot process effacement,19 from the standpoint of cell–matrix
interactions, would indicate that neither the presence of HS-
GAGs on agrin nor the agrin core protein itself is critical in
mediating foot process morphology. We believe that the
podocyte phenotype in the PEXTKO animal might possibly
be explained by a loss of ability of cell surface PGs, that is,
members of the syndecan family,24 to interact with HS-GAG
binding proteins such as laminin, which are present in the
GBM. In many cell systems, such as fibroblasts, syndecan–-
matrix interactions are important in the development of focal
contacts/adhesions,25 the primary syndecan involved in this
system is syndecan-4, which has also been shown to be
present in the glomerulus.26 Although the biology of the
syndecans has been well studied in other systems, little is
known about syndecan biology in the podocyte. Preliminary
data from our laboratory (S Chen and KJ McCarthy,
unpublished results) show that the loss of EXT1 in
immortalized podocytes results in loss of not only extra-
cellular matrix associated HS-GAGs but also cell surface HS-
GAGs. Thus, it is highly likely that in the PEXTKO mouse,
the loss of cell surface HS-GAGS could be playing a role in
directing podocyte behavior.
MATERIALS AND METHODS
Animals and animal care
Mice were housed under controlled conditions of light and
humidity in the Animal Resource Facility, an Association for
Assessment and Accreditation of Laboratory Animal Care-approved
facility, at LSU Health Sciences Center. All experimentation in the
studies was carried out under association for Assessment and
Accreditaation of Laboratory Animal Care-approved guidelines. Mice
transgenic for a 2.5P-Cre expression (podocin-Creþ ) construct were a
gift from Dr Lawrence Holzman (University of Michigan, Ann Arbor,
MI, USA).10 The Cre recombinase cassette in the expression construct
was under control of the human podocin (NPHS2 gene) promoter
permitting the expression of Cre recombinase specifically in glomerular
podocytes. Ext1flox/flox mice were a gift from Dr Yu Yamaguchi
(Burnham Institute for Biomedical Research, La Jolla, CA, USA). The
Ext1 alleles in these mice are flanked by a loxP site inserted into 50
untranslated region of exon 1 (230 nucleotides upstream of the
translation initiation site) and the other loxP site in the intron
downstream of exon 1. Both sets of mice had been previously crossed
with C57BL/6J mice to breed the mutations into the C57BL/6J genome
background. Podocin-Creþ mice were crossed with Ext1flox/flox to get
the Podocin-Cre/Ext1flox/ mice, which were then backcrossed to get
the Podocin-Cre/Ext1flox/flox mice.
Murine genotyping
Genotyping was carried out by PCR of tail snips using REDExtract-
N-AmpTM Tissue PCR Kit (Sigma Chemical, St Louis, MO, USA),
using the primers 50-GGAGTGTGGATGAGTTGAAG-30 (forward)
and 50-CAACACTTTCAGCTCCAGTC-30 (reverse).27 Cycling para-
meters for PCR were 951C, 15 min; 941C 1 min, 551C 1 min, 721C
1 min, repeat 40 cycles: 721C 10 min. Screening primers for podocin-
Cre were 50-GCATAACCAGTGAAACAGCATTGCTG-3 (forward)
and 50-GGACATGTTCAGGGATCGCCAGGCG-3 (reverse).28 Cycl-
ing parameters for the PCR were 951C, 15 min; 941C 1 min, 541C
1 min, 721C 1 min, repeat 35 cycles: 721C 10 min.
Immunohistochemistry
Unfixed renal tissue was embedded in OCT compound (Sakura
Finetek USA Inc. Torrence, CA, USA), snap frozen and stored at
201C until used and at 801C for long-term storage. Sections
(4mm) were cut and affixed to glass slides. Immunohistochemistry
was done as previously described.29 For comparative purposes (see
Microscopy and morphometric measures), age-matched kidney
sections from control and PEXTKO animals were affixed to the same
slide, permitting both sets of tissues to be immunostained under
similar conditions, thus avoiding possible differences in staining
intensity arising from variances in staining conditions. The following
primary antibodies were used in the study: (1) anti-agrin (1:50,
K-17:sc-6166; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
which recognizes an epitope present within the last 50 AA of agrin;
(2) rat monoclonal anti-perlecan antibody (1:100, clone A7L6,
Upstate Biotechnology, Lake Placid, NY, USA); (3) rat anti-laminin
g1 chain (Clone A5 1:100, Millipore Inc., Billerica, MA). (4) anti-HS
(1:2, HS4C3). Antibody HS4C3 recognizes N- and O-sulfated HS
domains, especially 3-O sulfated ones, which are typically present in
the GBM.30–32 Primary antibodies were localized using species-specific
Cy-2 or Cy-3-conjugated secondary antibody (1:100; Jackson Immuno-
research Laboratories, West Grove, PA, USA). In the case of
immunodetection on mouse tissues with phage display-derived
antibodies (HS4C3), a monoclonal mouse anti-VSV antibody (1:100
clone P5D4; Sigma Chemical) conjugated to Cy-3 was used.
Glomerular C-6-sulfate GAG localization was done using a mouse
monoclonal antibody, 3B3, which specifically recognizes a C-6-sulfate
neo-epitope33 present on C-6 PGs after prior treatment with
chondroitinase ABC (0.4 U/ml; Seikagaku Corporation, Tokyo, Japan).
Microscopy and morphometric measures
Digital images of the specimens were acquired using an Olympus IX-70
microscope equipped for epifluorescent illumination. The microscope
was interfaced to a Hamamatsu Orca camera (Hamamatsu, Bridge-
water, NJ, USA), the signal from which was ported to a Macintosh
Power PC hosting the imaging acquisition/analysis software I-Vision-
Mac (BioVision Technologies, Exton, PA, USA). To determine
differences in relative fluorescence intensity between age-matched
control and PEXTKO animals, slides with age-matched control and
PEXTKO paired tissue sections were immunostained as described
above to ensure consistency of immunoreagents during the staining
process. During imaging, the length of camera exposure was set to the
brightest immunofluorescence intensity between the two specimens to
limit pixel saturation. Subsequent imaging of both paired specimens
was done at the set exposure. Morphometric measures of glomerular
area on frozen sections (20 glomeruli per animal, three animals per
group) were done using a planimetry subroutine in I-Vision-Mac as
previously described.34 Microtome digital deconvolution software
(Vaytek Inc., Fairfield, IA, USA) was used to deconvolve 0.1mm-step
image stacks of serially acquired focal planes to generate confocal
images of immunostained glomeruli (Figure 4a–f).
In vivo labeling of anionic sites
To further investigate changes in the density of polyanionic sites in the
GBM of glomeruli from PEXTKO animals compared to control
animals, three animals per group (2 and 8 months of age) were
injected intracardially with 50ml of a 0.5% polyethyleneimine solution
(average molecular weight 25 000; Polysciences, Warrington, PA,
USA) in a manner similar to that described by Schurer et al.35 At 1 h
post-injection, the animals were killed, the kidneys were removed and
processed for electron microscopy studies (see below).
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Electron microscopy
Electron microscopy studies were done as previously described.36
Briefly, kidneys from control and PEXTKO mice were minced in
1 mm2 pieces and fixed in 2.5% glutaraldehyde and 2% formalde-
hyde in 0.1 M Sorenson’s phosphate buffer (pH 7.4) overnight
followed by postfixation in 2% osmium tetroxide in 0.1 M Sorenson’s
phosphate buffer for 2 h. Subsequently, the tissues were dehydrated
in a graded series of ethanol and propylene oxide solutions and
embedded in epoxy resin (Durcupan ANC Fluka Araldite; Sigma
Chemical). Tissue sections were cut at 80 nm thickness using a
Reichert Ultracut E Ultramicrotome (Leica Microsystems, Ban-
nockburn, IL, USA) and stained with uranyl acetate and lead citrate
as previously described.36 Specimens were imaged using a Phillips
CM-10 electron microscope. For quantification of BM labeling, a
grid corresponding to 500 nm 500 nm squares was superimposed
over scanned electron micrographs. The number of PEI particles per
500 nm length of GBM were counted for three capillary walls per
glomerulus from five glomeruli from each animal.
Urinalysis
For SDS-PAGE analysis of urinary proteins, urine was either
collected at the time of killing (acute) or for 24 h urinary excretion,
mice were housed in metabolic cages (Nalgene, Nalge Nunc
International, Rochester, NY, USA). For SDS-PAGE analysis, 20 ml
of urine from transgenic or control mice was electrophoresed on a
4–12% SDS-PAGE gel (Invitrogen, Carlsbad, CA, USA) followed by
silver staining. Images of the gels were digitized using a Kodak
2000MM imaging workstation. For additional urinalysis, spot urines
were collected from control and PEXTKO mice (2 and 8 months of
age, five animals per group). Urinary albumin was measured by
ELISA according to the manufacturer’s instructions (Albuwell M;
Exocell, Philadelphia, PA, USA); urinary creatinine was done using a
modified alkaline picrate method (Creatinine Companion; Exocell)
according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was done by ANOVA with post hoc testing
(Bonferonni–Dunn test) using the Statview software package.
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Note: A recent report by Roberts and Gleadle (JASN doi: 10.1681/
ASN.2007080842, published online 23 January 2008) demonstrated a
renal phenotype in the case of a 37-year-old woman with hereditary
multiple exostoses (HMEs). Sequencing of the EXT1 gene from this
patient showed a type 2 frameshift mutation (238 delA), which would
affect the downstream gene product from the affected allele. The
patient presented with peripheral edema had 24 g/dl proteinuria,
23 g/l albuminuria, and a serum creatinine of 1.1 mg/dl. Renal biopsy
showed mesangial expansion, accumulation of fibrillar collagen in the
mesangium and capillary walls, and modest podocyte foot process
effacement. In comparison to the mouse data in our report, both
phenotypic and functional changes reported in the case study are far
more severe. This difference could be a reflection of the fact that in
the human condition of HME, there would be a global
haploinsufficiency of the expression of EXT1 within all cells that
would normally express EXT1 in the patient. More likely than not,
HS-GAG assembly in mesangial cells would also be affected in HME.
In our model, Ext1 is not affected in mesangial cells since they remain
capable of assembling HS-GAG (Figure 4). Although the glomeruli
from the PEXTKO mouse undergo hypertrophy, mesangial expansion
does not occur in the PEXTKO glomeruli (S Chen and KJ McCarthy,
unpublished results). Thus, the loss of EXT1 activity in mesangial cells
may be directly contributory to the progression of mesangial
expansion seen in the case study.
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Figure S1.
Supplementary material is linked to the online version of the paper at
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